凱萊英(06821.HK)部分董事、高級管理人員和核心技術及業務人員增持公司A股實施完成
格隆匯3月10日丨凱萊英(06821.HK)公吿,凱萊英醫藥集團(天津)股份有限公司(以下簡稱“公司”)部分董事、高級管理人員和其他核心技術及業務人員擬自2024年9月12日起6個月內增持公司A股股份,增持金額不低於人民幣2,000萬元(含)。
本次增持實施情況:截至本公吿披露日,公司部分董事、高級管理人員和其他核心技術及業務人員通過深圳證券交易所證券交易系統集中競價交易方式累計增持公司股份398,394股,增持金額合計2,733.37萬元,本次增持計劃實施完畢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.